JP2021530559A5 - - Google Patents

Info

Publication number
JP2021530559A5
JP2021530559A5 JP2021520287A JP2021520287A JP2021530559A5 JP 2021530559 A5 JP2021530559 A5 JP 2021530559A5 JP 2021520287 A JP2021520287 A JP 2021520287A JP 2021520287 A JP2021520287 A JP 2021520287A JP 2021530559 A5 JP2021530559 A5 JP 2021530559A5
Authority
JP
Japan
Prior art keywords
compound according
hydrogen
compound
halogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021520287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530559A (ja
JP7373170B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/038622 external-priority patent/WO2019246603A1/en
Publication of JP2021530559A publication Critical patent/JP2021530559A/ja
Publication of JP2021530559A5 publication Critical patent/JP2021530559A5/ja
Application granted granted Critical
Publication of JP7373170B2 publication Critical patent/JP7373170B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021520287A 2018-06-22 2019-06-22 ジヒドロオロト酸デヒドロゲナーゼ阻害のための方法及び組成物 Active JP7373170B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688612P 2018-06-22 2018-06-22
US62/688,612 2018-06-22
PCT/US2019/038622 WO2019246603A1 (en) 2018-06-22 2019-06-22 Methods and compositions for inhibition of dihydroorotate dehydrogenase

Publications (3)

Publication Number Publication Date
JP2021530559A JP2021530559A (ja) 2021-11-11
JP2021530559A5 true JP2021530559A5 (https=) 2022-06-30
JP7373170B2 JP7373170B2 (ja) 2023-11-02

Family

ID=68984309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021520287A Active JP7373170B2 (ja) 2018-06-22 2019-06-22 ジヒドロオロト酸デヒドロゲナーゼ阻害のための方法及び組成物

Country Status (14)

Country Link
US (3) US11312686B2 (https=)
EP (2) EP4438042A3 (https=)
JP (1) JP7373170B2 (https=)
KR (1) KR102821649B1 (https=)
CN (1) CN112672744B (https=)
AU (2) AU2019288813B2 (https=)
BR (1) BR112020026308A2 (https=)
CA (1) CA3103557A1 (https=)
ES (1) ES2994093T3 (https=)
IL (1) IL279586B (https=)
MX (1) MX2021000143A (https=)
SG (1) SG11202012029PA (https=)
WO (1) WO2019246603A1 (https=)
ZA (1) ZA202007620B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
AU2020412805A1 (en) * 2019-12-26 2022-07-14 Hendrix College Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-CD38 therapeutic agent
WO2021134042A1 (en) * 2019-12-26 2021-07-01 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase
AU2021236757A1 (en) * 2020-03-20 2022-10-13 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
WO2021189018A1 (en) 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
CN113943312A (zh) * 2020-07-17 2022-01-18 轶诺(浙江)药业有限公司 一类肠道裂解型共药及其制备和用途
CN117915938A (zh) * 2021-06-30 2024-04-19 俄亥俄州国家创新基金会 用于与抗cd47-sirpα治疗剂组合抑制二氢乳清酸脱氢酶的方法和组合物
CN115896025B (zh) * 2021-08-20 2025-08-26 合肥中科普瑞昇生物医药科技有限公司 人原代急性髓系白血病细胞的培养基及培养方法
EP4436579A4 (en) * 2021-11-22 2025-10-22 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR TARGETING ALTERNATIVE METABOLISM IN CONJUNCTION WITH FLT3 INHIBITOR-MEDIATED ANTILEUKEMIA ACTIONS
CN115532290B (zh) * 2022-10-13 2024-04-30 浙江昌海制药有限公司 一种特定晶面选择性氢化催化剂及其制备方法和应用
WO2025227007A1 (en) * 2024-04-26 2025-10-30 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2888346A (en) * 1955-08-22 1959-05-26 Gen Aniline & Film Corp Ultra-violet absorbing compounds
AU2896097A (en) * 1996-05-10 1997-12-05 Novartis Ag Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation
WO2001024785A2 (en) 1999-10-01 2001-04-12 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
BR0310026A (pt) * 2002-05-17 2005-02-15 Aventis Pharma Sa Uso de docetaxel/doxorrubicina/ciclofosfamida em terapia adjuvante de câncer de mama e ovariano
AU2014209107B2 (en) * 2013-01-28 2018-04-12 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
RS57962B1 (sr) 2013-02-25 2019-01-31 Aurigene Discovery Tech Ltd Derivati trisupstituisanog benzotriazola kao inhibitori dihidroorotat oksigenaze
US20190192501A1 (en) 2016-08-23 2019-06-27 Icahn School Of Medicine At Mount Sinai Methods for treating pten-mutant tumors

Similar Documents

Publication Publication Date Title
JP2021530559A5 (https=)
JP2023052094A5 (https=)
JP2024516371A5 (https=)
JP2024543976A5 (https=)
JP2022551185A5 (https=)
JP2004516314A5 (https=)
JP2016518434A5 (https=)
JP2007501859A5 (https=)
JP2017537940A5 (https=)
JP2008503515A5 (https=)
JP2018533593A5 (https=)
JP2021525787A5 (https=)
RU2013156074A (ru) Диазакарбазолы и способы применения
JP2014505017A5 (https=)
JP2015512943A5 (https=)
JP2010529994A5 (https=)
JP2023504544A5 (https=)
JP2013518036A5 (https=)
RU2012135698A (ru) Способ и композиция
JP2020504184A5 (https=)
JP2004523478A5 (https=)
RU2009128970A (ru) Производные изосорбидмононитрата для лечения кишечных заболеваний
JP2025183283A5 (https=)
RU2006139140A (ru) Средства и способы для лечения нарушений свертываемости
JP2010505869A5 (https=)